Here's Why Skillz Stock Suddenly Spiked TodayMotley Fool2021-09-01 07:57Skillz Inc+7.05%PostSomeone just made a multimillion-dollar bet on this company.What happenedShares of mobile-gaming platform Skillz Inc were trading modestly higher for most of Tuesday's session. But around 1:30 p.m. EDT, the stock suddenly spiked higher, seemingly out of nowhere. As of this writing, the stock is up 12%. After a little digging, it seems that some chatter on social news platform Reddit could be responsible for the jump.
"The proposed merger with Advaxis is a unique opportunity for Biosight to build a leading public company in oncology, with a diversified clinical pipeline in both hematological malignancies and solid tumors. The combined company will have the demonstrated expertise and strong balance sheet to advance its lead programs towards multiple anticipated milestones over the next 12 to 18 months."Dr. Ruth Ben Yakar, CEO of Biosigh
Castor Maritime Inc. Announces a New Charter Agreement at a Daily Gross Charter Rate of $39,500 For Its Capesize VesselCastor Maritime Inc.Fri, July 30, 2021, 9:00 PM · 4 min readLIMASSOL, Cyprus, July 30, 2021 (GLOBE NEWSWIRE) -- Castor Maritime Inc. (NASDAQ: CTRM), (“Castor”, or the “Company”) a diversified global shipping company,
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split
Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace TherapeuticsGlobeNewswire2021-07-29 12:30LAVAL, Québec, July 29, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces a reminder that it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases, as well as topics related to the annual and special meeting of